Cymbalta Fibromyalgia Approval Sets Another REMS Precedent
Executive Summary
FDA's approval of Lilly's Cymbalta (duloxetine) for treatment of fibromyalgia sets another precedent in the new era of Risk Evaluation and Mitigation Strategies: the agency will not necessarily seek a formal REMS for products already accompanied by mandatory medication guides
You may also be interested in...
Cymbalta Pregnancy Risk Fit FDA's New Power To Mandate Post-Market Study
FDA's application of its new ability to require - as opposed to request - post-marketing studies under the FDA Amendments Act is on display in the review of a fibromyalgia claim for Lilly's Cymbalta (duloxetine)
Cymbalta Pregnancy Risk Fit FDA's New Power To Mandate Post-Market Study
FDA's application of its new ability to require - as opposed to request - post-marketing studies under the FDA Amendments Act is on display in the review of a fibromyalgia claim for Lilly's Cymbalta (duloxetine)
Waking Up To REMS: Sponsors Should Test Risk Management In Phase III
With Risk Evaluation and Mitigation Strategies supplanting Risk Minimization Action Plans, drug sponsors would be well served to begin preparing for negotiations over risk management plans during product development